Biblio

Author Title [ Type(Desc)] Year
Filters: Author is Mei, Matthew  [Clear All Filters]
Journal Article
Slavin TP, Teh JBerano, Weitzel JN, Peng K, F Wong L, Qin H, Wang J, Wu X, Mei M, Pillai R, et al. Association between Clonal Hematopoiesis and Late Non-Relapse Mortality after Autologous Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2019.
Ladbury C, Mei M, Kafaja S, Nall J, Han C, Dandapani S, Forman S, Wong JYc. Autologous Stem Cell Transplantation with Intensity Modulated Total Body Irradiation Conditioning for Systemic Sclerosis. Int J Radiat Oncol Biol Phys. 2023.
Mei M, Wondergem MJ, Palmer JM, Shimoni A, Hasenkamp J, Tsai N-C, Simpson J, Nademanee A, Raubitschek A, Forman SJ, et al. Autologous transplantation for transformed non-Hodgkin lymphoma using an yttrium-90 ibritumomab tiuxetan conditioning regimen. Biol Blood Marrow Transplant. 2014.
Salhotra A, Mei M, Stiller T, Mokhtari S, Herrera AF, Chen R, Popplewell L, Zain J, Ali H, Sandhu K, et al. Outcomes of patients with recurrent and refractory lymphoma undergoing allogeneic hematopoietic cell transplantation with BEAM conditioning and sirolimus and tacrolimus based GVHD prophylaxis. Biol Blood Marrow Transplant. 2018.
Mei M, Gupta R, O'Donnell M, Malki MMAl, Aldoss I, Ali H, Farol L, Snyder D, Forman SJ, Nakamura R, et al. Post-allogeneic eculizumab as prophylaxis against hemolysis and thrombosis for patients with hematologic disorders associated with PNH clones. Biol Blood Marrow Transplant. 2019.
Mei M, Palmer J, Tsai NNi-Chun, Simpson J, O'Hearn J, Stein A, Forman S, Spielberger R, Cai J-L, Htut M, et al. Results of a Phase II Trial of Allogeneic Hematopoietic Stem Cell Transplantation Using Y-Ibritumomab Tiuxetan (Zevalin) in Combination With Fludarabine and Melphalan in Patients With High-Risk B-Cell Non-Hodgkin's Lymphoma. Clin Lymphoma Myeloma Leuk. 2023.